The strong results from the previously presented EFECT study have now been published in the scientific, and highly renowned, European Journal of Cancer (impact factor 7.191 which equals to top 3% of scientific journal ranking).
The extra general meeting ("EGM") of Biovica International AB (publ) ("Biovica" or the "Company") was held today on 2 May 2019 and the following resolutions were passed by the meeting. Resolution regarding approval of the board of directors' resolution to issue new class B shares with deviation from the shareholders' preferential rights
Uppsala, Sweden, April 10, 2019: Biovica has agreed on a collaboration with IBL-America for sales of DiviTum® for the research market in the US. The partnership will further increase the commercial activities for this customer segment on the single largest market for Biovica.
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting on Thursday 2 May 2019 at 13.00 pm CET at Baker & McKenzie's premises at Vasagatan 7 in Stockholm. The doors to the meeting will open at 12.45 pm CET. Right to attend and notification Shareholders [...]
Biovica completes a directed new share issue of SEK 60 million and calls for an extraordinary general meeting
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Biovica International AB (publ) (”Biovica” or the ”Company”) has, subject to the extraordinary general meeting subsequent approval and as communicated in the Company’s press release earlier today, resolved to carry out a directed new share issue of Class B Shares at a subscription price of SEK 10 per share. The directed new share issue was substantially over-subscribed with large interest from institutional investors in the Nordics and Europe. Through the directed new share issue and subject to the approval of the extraordinary General Meeting, the Company will receive proceeds amounting to SEK 60 million. The notice convening the EGM will be published separately today.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Biovica International AB (publ) (”Biovica” or the ”Bolaget”) today announces its intention to undertake a directed share issue of Class B shares of SEK 45-60 million to institutional investors. The Company has engaged Pareto Securities AB (”Pareto Securities”) to investigate the conditions for a new issue of Class B shares through a so-called accelerated bookbuilding.
Uppsala, Sweden, April 1, 2019. Biovica receives an additional patent on the US market for the company PCR-based product.
Significant events during the third quarter · Abstract was presented at San Antonio Breast Cancer Symposium · New office and staff in USA Significant events after the end of the period · Abstract to be presented at AACR in April · Shares now traded on Nasdaq First North Premier · Lars Holmqvist elected as new Chairman · Two new customers, a pharmaceutical company and a CRO, and sales of SEK 1.5 million.
Uppsala, Sweden, March 20, 2019. Lars Holmqvist was elected Chairman of the Board and a warrant program of 175,000 options to the Board was approved.
Uppsala, the 19th of March 2019. Two new customers have purchased DiviTum®-kits in order to evaluate response to treatment in breast cancer studies. The customers are pharma- and CRO-companies (Contract Research Organization) based in US and Europe.